PHARMENAPHARMENAPHARMENA

PHARMENA

No trades
See on Supercharts

PHR fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. It focuses on clinical research on innovative anti-atherosclerotic medicinal product, production of innovative dermatological products, and introduction of innovative dietary supplement used for special nutritional needs in the prevention of atherosclerosis. It distributes its products under the Menavitim, Dermena, Allerco, and Thermi brands. The company was founded by Jerzy Gebicki on November 12, 2002 and is headquartered in Lodz, Poland.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

PHR does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company